5.01
0.60%
-0.03
Eagle Pharmaceuticals Inc stock is currently priced at $5.01, with a 24-hour trading volume of 100.87K.
It has seen a -0.60% decreased in the last 24 hours and a -22.20% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $5.08 pivot point. If it approaches the $4.98 support level, significant changes may occur.
Eagle Pharmaceuticals Inc Stock (EGRX) Financials Data
Eagle Pharmaceuticals Inc (EGRX) Revenue 2023
EGRX reported a revenue (TTM) of $257.55 million for the quarter ending June 30, 2023, a -5.38% decline year-over-year.
Eagle Pharmaceuticals Inc (EGRX) Net Income 2023
EGRX net income (TTM) was $11.95 million for the quarter ending June 30, 2023, a -47.57% decrease year-over-year.
Eagle Pharmaceuticals Inc (EGRX) Cash Flow 2023
EGRX recorded a free cash flow (TTM) of -$9.39 million for the quarter ending June 30, 2023, a -126.60% decrease year-over-year.
Eagle Pharmaceuticals Inc (EGRX) Earnings per Share 2023
EGRX earnings per share (TTM) was $0.91 for the quarter ending June 30, 2023, a -48.30% decline year-over-year.
Eagle Pharmaceuticals Inc Stock (EGRX) Latest News
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
GlobeNewswire Inc.
Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City
GlobeNewswire Inc.
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q
GlobeNewswire Inc.
Eagle Pharmaceuticals Announces Management Change
GlobeNewswire Inc.
Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
Zacks Investment Research
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Cap:
|
Volume (24h):